Literature DB >> 22352873

American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery.

Sally E Carty1, Gerard M Doherty, William B Inabnet, Janice L Pasieka, Gregory W Randolph, Ashok R Shaha, David J Terris, Ralph P Tufano, R Michael Tuttle.   

Abstract

BACKGROUND: Thyroid cancer specialists require specific perioperative information to develop a management plan for patients with thyroid cancer, but there is not yet a model for effective interdisciplinary data communication. The American Thyroid Association Surgical Affairs Committee was asked to define a suggested essential perioperative dataset representing the critical information that should be readily available to participating members of the treatment team.
METHODS: To identify and agree upon a multidisciplinary set of critical perioperative findings requiring communication, we examined diverse best-practice documents relating to thyroidectomy and extracted common features felt to enhance precise, direct communication with nonsurgical caregivers.
RESULTS: Suggested essential datasets for the preoperative, intraoperative, and immediate postoperative findings and management of patients undergoing surgery for thyroid cancer were identified and are presented. For operative reporting, the essential features of both a dictated narrative format and a synoptic computer format are modeled in detail. The importance of interdisciplinary communication is discussed with regard to the extent of required resection, the final pathology findings, surgical complications, and other factors that may influence risk stratification, adjuvant treatment, and surveillance.
CONCLUSIONS: Accurate communication of the important findings and sequelae of thyroidectomy for cancer is critical to individualized risk stratification as well as to the clinical issues of thyroid cancer care that are often jointly managed in the postoperative setting. True interdisciplinary care is essential to providing optimal care and surveillance.

Entities:  

Mesh:

Year:  2012        PMID: 22352873     DOI: 10.1089/thy.2011.0423

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

2.  Diagnostic, therapeutic and health-care management protocol in thyroid surgery: a position statement of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB).

Authors:  L Rosato; C De Crea; R Bellantone; M L Brandi; G De Toma; S Filetti; P Miccoli; F Pacini; M R Pelizzo; A Pontecorvi; N Avenia; L De Pasquale; M G Chiofalo; A Gurrado; N Innaro; G La Valle; C P Lombardi; P L Marini; G Mondini; B Mullineris; L Pezzullo; M Raffaelli; M Testini; M De Palma
Journal:  J Endocrinol Invest       Date:  2016-04-08       Impact factor: 4.256

Review 3.  New approaches to providing individualized diabetes care in the 21st century.

Authors:  Priscilla W Powell; Sarah D Corathers; Jennifer Raymond; Randi Streisand
Journal:  Curr Diabetes Rev       Date:  2015

4.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors:  R Michael Tuttle; Ali S Alzahrani
Journal:  J Clin Endocrinol Metab       Date:  2019-03-15       Impact factor: 5.958

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 6.  Microscopic positive surgical margins in thyroid carcinoma: a proposal for thyroid oncology teams.

Authors:  Alvaro Sanabria; Luiz P Kowalski; Iain J Nixon; Ricard Simo
Journal:  Langenbecks Arch Surg       Date:  2021-02-08       Impact factor: 3.445

Review 7.  [Hemithyroidectomy or total thyroidectomy for low-risk papillary thyroid cancer? : Surgical criteria for primary and secondary choice of treatment in an interdisciplinary treatment concept].

Authors:  H Dralle; F Weber; A Machens; T Brandenburg; K W Schmid; D Führer-Sakel
Journal:  Chirurgie (Heidelb)       Date:  2022-09-19

Review 8.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

9.  New Recommendations for Extent of Thyroidectomy and Active Surveillance for the Treatment of Differentiated Thyroid Cancer.

Authors:  Ralph P Tufano; Maisie Shindo; Ashok R Shaha
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-07-01       Impact factor: 6.223

10.  Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma.

Authors:  Maureen D Moore; Emily Postma; Katherine D Gray; Timothy M Ullmann; James R Hurley; Stanley Goldsmith; Vivian R Sobel; Aaron Schulman; Theresa Scognamiglio; Paul J Christos; Erin Hassett; Jessica Luick; Dana Whitehall; Rasa Zarnegar; Thomas J Fahey
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.